Proteomic insight of seminal plasma in spinal cord injured men submitted to oral probenecid treatment for improved motility

Mariana Camargo, Emad Ibrahim, Teodoro C. Aballa, Karina H.M. Cardozo, Valdemir M. Carvalho, Charles M Lynne, Nancy L. Brackett, Ricardo P. Bertolla

Research output: Contribution to journalArticle

Abstract

Objective: To observe the seminal plasma proteomic composition in men with spinal cord injury orally treated with probenecid, in order to observe pathways associated with increased sperm motility. Study design: Prospective study. Setting: Miami Project to Cure Paralysis–University of Miami/Miller School of Medicine. Participants: Nine men with spinal cord injury, who agreed to participate in the study. Intervention: Oral treatment with probenecid – 500 mg per day for one week, then 500 mg twice daily [1000 mg total] per day for three weeks. Outcome measures: Semen analysis as per WHO 2010 guidelines, and seminal plasma proteomics analysis by LC-MS/MS. Results: In total, 783 proteins were identified, of which, 17 were decreased, while 6 were increased after treatment. The results suggest a new pathway that could be treated by the decrease of biglycan after probenecid treatment. Conclusion: Oral treatment with probenecid is able to alter the seminal plasma proteome, in pathways that explain decreased innate immune response.

Original languageEnglish (US)
JournalJournal of Spinal Cord Medicine
DOIs
StateAccepted/In press - Jan 1 2020

Keywords

  • Probenecid
  • Proteomics
  • Seminal plasma
  • Spinal cord injury

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Proteomic insight of seminal plasma in spinal cord injured men submitted to oral probenecid treatment for improved motility'. Together they form a unique fingerprint.

  • Cite this